We can support it to happen
Crystallization development and upscaling is always a challenge since the product properties must meet up to the intended functionality, stability, and safety of the final product. Our team has more than 30 years of experience in the field and are leading experts in the area globally.
Our experts are experienced in supporting crystallization processes and supporting product development, by providing deeper insight into the solid-state properties of drug substance.
About Magle Group
Magle AB (formed in 1995 as a pure development company) acquired Chemoswed AB (formed in 1944 as a manufacturing company) in 2016 before merging the companies in 2017 to form Magle Chemoswed. In 2019, Adroit Science AB was acquired to increase the development services segment. In 2021, PharmaCept GmbH was acquired as a first step to develop a sales and marketing organization for DSM products. In 2024 Magle Group welcomed Magle Biopolymers - a CDMO part of the group focusing on Dextran technology, and Magle BioPharma - a stem cell based CDMO.
Already working at Magle Group?
Let’s recruit together and find your next colleague.